BioMedNewsBreaks – IBN, BioMedWire to Provide Dedicated Media Coverage for Upcoming BioPharma Nexus Events

InvestorBrandNetwork (“IBN”), a dynamic communications organization, today announced its collaboration with BioPharma Nexus as an official media partner for its events this month. In addition, BioMedWire, a specialized communications platform dedicated to the life sciences sector and a key part of IBN’s Dynamic Brand Portfolio (“DBP”), will serve as an official media partner. For each of the events, IBN and BioMedWire will leverage advanced communications tools to provide dedicated coverage, including syndicated article dissemination throughout IBN’s extensive network of 5,000+ strategic partners, and offer updates on each event via IBN’s influential social media accounts. “It is a pleasure to work with IBN and BioMedWire,” said Asad Ali, head of operations for BioPharma Nexus. “They have proved invaluable in developing our targeted outreach, delivering high visibility to our sponsors, partners and speakers across multiple audiences via trusted brands.”

To view the full press release, visit https://ibn.fm/j1lhF

About IBN

IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (“DBP”), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Advances Toward NDA Submission for ALS Therapy

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company…

3 hours ago

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Signs Deal with Worldwide Leader in Specialized Diagnostics 

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced a Research License and…

7 hours ago

BioMedNewsBreaks — Gyre Therapeutics (NASDAQ: GYRE) Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone

Gyre Therapeutics (NASDAQ: GYRE) has made strong progress through the first three quarters of FY2025,…

7 hours ago

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Reports Study Showing Comparable Accuracy Between HeartBeam System and Standard 12-Lead ECG in Detecting Arrhythmias

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care with personalized insights,…

1 day ago

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Closes Acquisition of Dura Medical

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that its wholly owned subsidiary HOPE…

1 day ago

BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Completes Reverse Stock Split to Support Growth Plans

HealthLynked (OTCQB: HLYK) has completed a reverse stock split as part of its strategy to…

4 days ago